You’ve spent months working on the asset. The clinical strategy has been debated. The data have been reviewed from every angle. The
When you read the Pharma news sites and analysis on LinkedIn about drug patent cliffs, you might think pharmaceutical companies are sitting
Intro Teams often fail not because of a lack of data, but because of research that confirms what they already believe. The
Whenever analogs come up in pharma strategy, someone usually says: “But that situation wasn’t the same as ours.” In recent weeks, I’ve
Over recent months, I’ve been exploring novel diagnostic tools, with a particular focus on digital cognitive assessments. Along the way, I came
Every Project Plan Assumes People Don’t Leave. Reality Check: They Do. A few years ago, I took over a project that was
This past month, I have been immersed in obesity science, and one thing’s clear: not every pathway moves the scales. After dissecting
It has been a quiet summer on the post front with holidays and then a few active projects keeping us very but,
Intro At the end of May, Eli Lilly announced a $1 billion deal with Site One Therapeutics, a company developing a Nav1.8
With the sun out and a few projects wrapping up, I have enjoyed longer dog walks and catching up on new pharmaceutical
Introduction: Spotting the Threat You Didn’t Expect This week’s article is based on a project I completed earlier this year as part
Early this week, I joined Chris Spivey on PharmaTech.com’s Behind the Headlines to discuss several of the previous week’s significant life science
~1.5 years ago I was reading a Financial Times article (FT.com) on obesity drugs and their order to market when my critical
Following last week’s post on the slow activity in M&A in 2025 so far (Sivan-Consulting), we now have some activity picking up,
It has been a bit of a writing hiatus as I have been in the middle of delivering a few short, intense